Abstract:Ponesimod is an oral, selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that has been approved for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive multiple sclerosis. As a member of the sphingosine-1-phosphate modulator class, Ponesimod exerts its therapeutic effects by selectively binding to the S1P1 receptor, leading to internalization and degradation of the receptor. This functional antagonism results in the sequestration of lymphocytes within lymph nodes, thereby reducing their migration into the central nervous system and limiting inflammatory damage associated with MS relapses.
Ponesimod offers several pharmacokinetic advantages over earlier agents in the same class, such as a shorter half-life and greater receptor selectivity, which may translate into a more favorable safety and tolerability profile. Clinical efficacy has been demonstrated in the phase III OPTIMUM trial, which showed significant reductions in the annualized relapse rate, MRI lesion burden, and fatigue symptoms when compared to teriflunomide. The drug also has a rapid onset and offset of action, which provides clinicians with greater flexibility in managing therapy interruptions or transitions.
This review provides a comprehensive overview of Ponesimod's mechanism of action, pharmacokinetics, efficacy in clinical trials, safety considerations, and its place within the current landscape of disease-modifying therapies for MS.
